Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~- Healthy male or female subjects~Exclusion criteria:~- Any relevant deviation from healthy condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- FDC first, fasted (Type: EXPERIMENTAL): Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
- Single tablets first, fasted (Type: EXPERIMENTAL): single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
- FDC first, fed (Type: EXPERIMENTAL): Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
- Single tablets first, fed (Type: EXPERIMENTAL): single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition

Based on this trial design, predict the completion outcome and termination type (if applicable).